GMP for Capsule Manufacturing: Controls That Protect Quality

In short: Capsules are only as good as the system around them. This guide shows the GMP controls that matter most in capsule manufacturing in India: quality system, premises, shell and humidity control, filling checks, testing, records and audits. It suits production, QA and QC staff and pharmacy students.

Why GMP matters for capsules

Good Manufacturing Practice (GMP) makes sure that every batch is made and checked to the standard its marketing authorisation requires. Capsules carry particular risks: a wrong or uneven fill weight changes the dose, shells react to humidity, powders can cross-contaminate between products, and damaged or poorly locked capsules reach patients as defects.

This article is a learning guide. It does not replace the regulations that apply to your site. In India these are the Drugs Rules, 1945 and Schedule M (see Regulatory framework). For the wider dosage-form context, see also Specific requirements for manufacture of oral solid dosage forms.

Key GMP steps for capsule manufacturing

1. Build a working quality management system (QMS)

The QMS covers everything from supplier approval and material receipt to batch release and complaints. It defines who is responsible for what, how changes and deviations are handled, and how quality decisions are made independently of production. A QMS that exists only on paper is the most common weakness found in inspections.

2. Design premises and equipment for the product

Premises should prevent mix-ups and contamination. For capsules this usually means:

• separate, clearly marked areas for material storage, dispensing, blending, filling, polishing/sorting and packing;
• controlled temperature and relative humidity where shells or hygroscopic powders are handled, with the limits set from the shell supplier’s data and your product’s stability needs (example in-house criterion, to be justified for your product);
• for capsule manufacture, a separate enclosed area that is air-conditioned and dehumidified, with an airlock, as Schedule M requires;
• dust extraction and pressure differentials that stop powder moving between rooms;
• smooth, cleanable surfaces, adequate lighting and ventilation;
• equipment qualified for its use, calibrated, and cleaned using a validated procedure.

3. Control materials, including empty capsule shells

Test and release every incoming active, excipient and shell lot before use, and buy only from approved suppliers. For shells, check identity, appearance and the supplier’s certificate against your specification, and store them as the supplier directs, since gelatin and other shell materials take up or lose moisture. Schedule M (Part VIII, section 5) asks that empty capsules are stored where they are protected from excessive heat and moisture. Dispense by weight or count with a second-person check and record it in the batch record.

4. Write procedures and batch records

Written procedures should cover dispensing, blending, filling, closing/locking, de-dusting and polishing, inspection, sampling, packing, cleaning and batch release. The batch manufacturing record should let anyone trace each step, the equipment, the operator and the checker. For documentation principles see Good documentation in the pharmaceutical industry (EudraLex Vol. 4).

5. Run in-process controls during filling

Typical in-process checks on a capsule filling line include fill weight (individual and average), shell locking and closure, appearance, and, where relevant, disintegration. How often to check and what limits to apply must come from your validated process and the applicable pharmacopoeia or specification. Any value shown in an example procedure is an example in-house criterion and must be justified for the product.

6. Test raw materials, in-process samples and finished capsules

Quality control tests the finished product against its approved specification. For capsules this normally includes description, identification, assay, content uniformity or weight variation, disintegration and/or dissolution, related substances, and microbial quality where required. Use the monograph or your approved specification for limits. In India the Indian Pharmacopoeia is the official standard; for USP markets, general chapter <1151> Pharmaceutical Dosage Forms describes capsules and <905> Uniformity of Dosage Units covers content uniformity and weight variation.

7. Train every person for the job they do

Personnel need initial and continuing GMP training: hygiene and gowning, equipment operation, cleaning, documentation, data integrity and the reporting of deviations. Record the training and check that it was understood, for example by observation or a short assessment.

8. Keep traceability from material to patient

Each lot of active, excipient and shell, each piece of equipment used, and each batch of finished capsules should be traceable in both directions. If a defect is found, you should be able to name the affected batches and recall them quickly. Line clearance records between batches support this.

9. Keep complete, accurate records

Records must be contemporaneous, legible, attributable and complete, whether paper or electronic. They cover specifications, process parameters, test results, deviations and batch release. Keep batch documentation at least 1 year after the expiry date of the respective product batch (EU GMP Part I, Chapter 4, section 4.11, which also allows for at least 5 years after certification by the Qualified Person if that is longer; 21 CFR 211.180(a)). Keep records longer if local law or the marketing authorisation requires.

10. Handle deviations and complaints

Report any departure from procedure, investigate its root cause, assess the effect on product quality, and decide on corrective and preventive action. See Handling of incidents and deviations.

11. Audit yourself regularly

Planned self-inspections by trained, independent staff show whether practice matches procedure, and the findings should be followed up and closed. WHO’s GMP main principles give guidance on self-inspection, quality audits and supplier audits. See Self-inspection and the GMP self-inspection checklist.

12. Improve continuously

Review trends in deviations, out-of-specification results, complaints and yields, and use the product quality review to decide what needs to change.

Regulatory framework

Indian manufacturers must meet Schedule M of the Drugs Rules, 1945 and the conditions of their manufacturing licence issued under the Drugs and Cosmetics Act, with CDSCO and the State licensing authorities overseeing compliance. CDSCO’s notification index lists revised Schedule M as G.S.R. 922(E), dated 28 December 2023, with a corrigendum, G.S.R. 666(E), dated 25 October 2024; later notifications, such as G.S.R. 127(E) of 11 February 2025, extended the implementation timeline for some manufacturers. Schedule M also requires you to inform the licensing authorities of serious quality problems with a product and of any intention to recall a defective product (Part I, sections 6.10 and 7.5). Which requirements and timelines apply to your site depends on your category and licence, so check the current notifications. Many sites also work to WHO, PIC/S or EU GMP standards for export markets.

Frequently asked questions

Why is humidity so important in capsule manufacturing? Shells take up or lose water depending on the surroundings. Too dry and they become brittle; too humid and they soften, stick or deform. Water also affects moisture-sensitive actives.

Do I need to test every capsule for fill weight? Not usually. Fill weight is checked by a sampling plan defined in your validated process, together with pharmacopoeial tests on the finished batch. The plan and limits come from your specification.

What is the most common cause of cross-contamination in capsule filling? Powder dust moving through air, equipment surfaces or people. Dust extraction, pressure differentials, line clearance and validated cleaning address it.

How long must capsule batch records be kept? At least 1 year after the expiry of the respective batch, and longer if local law or the marketing authorisation requires (see step 9).

References

• World Health Organization. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series No. 986, Annex 2, 2014. Official publication page; official PDF.
• Central Drugs Standard Control Organization, Government of India. G.S.R. 922(E): Notification of Schedule M of the Drugs Rules, 1945, 28 December 2023; G.S.R. 666(E): Corrigendum to G.S.R. 922(E), 25 October 2024; G.S.R. 127(E): Extension of timeline for implementation of Schedule M, 11 February 2025. CDSCO Gazette Notifications.
• European Commission. EudraLex Volume 4, EU GMP Part I, Chapter 4: Documentation, section 4.11 (retention of batch documentation).
• US FDA. 21 CFR 211.180: General requirements (record retention).
• United States Pharmacopeia. General chapter <1151> Pharmaceutical Dosage Forms and general chapter <905> Uniformity of Dosage Units (harmonised text, official 1 August 2023). USP–NF.
• Indian Pharmacopoeia Commission. Indian Pharmacopoeia, current edition. IPC.